Related Experiment Videos
Perospirone (Sumitomo Pharmaceuticals).
1Psychiatry Department, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Tomas.dePaulis@mcmail.vanderbilt.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
Summary
Perospirone, an atypical antipsychotic, was approved in Japan for schizophrenia treatment. It functions as a serotonin 5-HT2 and dopamine D2 antagonist, similar to risperidone.
Area of Science:
- Pharmacology
- Psychiatry
Background:
- Perospirone is an atypical antipsychotic agent developed by Sumitomo Pharmaceuticals.
- It acts as both a serotonin 5-HT2 antagonist and a dopamine D2 antagonist.
- Its pharmacological profile is comparable to other atypical antipsychotics, such as risperidone.
Purpose of the Study:
- To detail the development and market launch of perospirone in Japan.
- To outline the regulatory and commercial milestones achieved for perospirone.
Main Methods:
- Review of regulatory approval processes in Japan.
- Analysis of commercial agreements and sales forecasts.
Main Results:
- Perospirone received approval in Japan in December 2000.
- The drug was launched in Japan on February 8, 2001, following pricing agreements.
- Peak sales were forecast between yen 9-10 billion within six years post-launch.
Conclusions:
- Perospirone successfully navigated the Japanese regulatory and market entry process.
- The drug was positioned as a significant new treatment option for schizophrenia and psychoses.